AdisInsight

We publish a database of drugs, trials. deals and safety, based on trusted, scientifically sound data. Site notice

[AdisInsight @NewAdisInsight]

Join us for a FREE #webinar ‘Tracking the progress of #drugdevelopment and #clinicaltrials for Covid-19 using a specialist drug database’ To find out more and reserve your seat, click here: https://t.co/27XeRKCVlJ

[AdisInsight @NewAdisInsight]

Join us for a FREE #webinar ‘Tracking the progress of #drugdevelopment and #clinicaltrials for Covid-19 using a specialist drug database’ To find out more and reserve your seat, click here: https://t.co/VFu6JmuWWN

[AdisInsight @NewAdisInsight]

Join us for a FREE #webinar ‘Tracking the progress of #drugdevelopment and #clinicaltrials for Covid-19 using a specialist drug database’ To find out more and reserve your seat, click here: https://t.co/O1YMfOG3Ny

[AdisInsight @NewAdisInsight]

Are you attending @PharmaCIConf Asia this December? Visit us at our stand to see how #AdisInsight can help you and receive a FREE competitive intelligence report. To find out more and to pre-register your interest, click here: https://t.co/26Zq2y8TvS #PharmaCI

[Karen Mirabile @MirabileKaren]

⁦@NewAdisInsight⁩ is attending the ⁦@PharmaCIConf⁩ in Newark NJ!

[AdisInsight @NewAdisInsight]

It's day two @PharmaCIConf, don’t forget to visit our booth and get your FREE competitive intelligence report. #pharmaciconf #competitiveintelligence #AdisInsight

[Karen Mirabile @MirabileKaren]

@MirabileKaren is attending the PharmaCI Conference in Newark NJ. Stop by the @NewAdisInsight booth at the @PharmaCIConf to see how AdisInsight can help you and enter a chance to win an Amazon Echo!

[AdisInsight @NewAdisInsight]

Stop by our booth today @PharmaCIConf USA to see how #AdisInsight can help you and receive a FREE competitive intelligence report. #pharmaciconf

[AdisInsight @NewAdisInsight]

Are you attending @PharmaCIConf USA this September? Visit us at our stand to see how AdisInsight can help you and receive a FREE competitive intelligence report. To find out more and to pre-register your interest, click here: https://t.co/U2AC7YBFvn #pharmaciconf

[AdisInsight @NewAdisInsight]

Browse #diabetes #diabetes mellitus https://t.co/inlSVdYV7u from @Springernature. Free content in the form of a virtual issue PLUS two webinars on “Precision Diabetes” and “Future of Insulin”

[AdisInsight @NewAdisInsight]

Browse #alzheimer’s #dementia research https://t.co/VjoEzakqgf from @Springernature. Free content in the form of a virtual issue, explore the latest research on diagnosis, treatment and prevention by leveraging a variety of techniques and technologies.

[AdisInsight @NewAdisInsight]

Browse #cancertreatment research https://t.co/CkEyeo37V5 from @Springernature incl. webinar about "Innovations & Trends in #oncology" and white paper on “#biomarkers, #mutations and #moleculartargets”

[Caitlin Cricco @CaitlinCricco]

Have you viewed the @SpringerNature 5 Global Grand Challenges Infographic yet? Here's a snippet, but view the entire image here: https://t.co/WgTUXl66MA

[AdisInsight @NewAdisInsight]

Avatrombopag (#Doptelet®): First Global Approval – Reducing the bleeding risks of invasive procedures in patients with Chronic Liver Disease https://t.co/pf2e6jppRF

[AdisInsight @NewAdisInsight]

@SpringerNature has compiled a list with more than 250 research funders and institutions that fund publication costs. Discover the funding available to you and benefit from our free OA support service. https://t.co/mfvgucp7Zl

[AdisInsight @NewAdisInsight]

Erenumab (#AIMOVIG™) developed by #Amgen and #Novartis: First Global Approval in US followed by Positive CHMP Opinion – Once-monthly prophylactic approach for adults with #Migraine https://t.co/XRLIx7RwPD

[Springer Nature Authors @SN_Authors]

What does it take to write a book that doesn't fit into the traditional academic framework? Tips and advice from a Springer Nature author on the Source blog. https://t.co/0M8v9Slvhi

[AdisInsight @NewAdisInsight]

#Dupilumab (#Dupixent®): #CADTH Publishes Negative Recommendation for Reimbursement in Canada https://t.co/xZrtjajpyk

[AdisInsight @NewAdisInsight]

Durvalumab (#IMFENZI®): Follow up Approval for #NSCLC in Japan https://t.co/vsbxQPc7LM

[AdisInsight @NewAdisInsight]

Want to present at this year’s @SpringerNature Better Science through Better Data event in London? Wednesday 14th November 2018. Apply today #scidata18 #ResearchData
https://t.co/Bhxs2O3lGx